You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):研究發現VV116在RSV多個敏感細胞繫上具有優異的抗病毒效果

格隆匯4月18日丨君實生物(01877.HK)宣佈,由公司控股子公司上海君拓生物醫藥科技有限公司與蘇州旺山旺水生物醫藥有限公司合作開發的口服核苷類抗SARS-CoV-2藥物VV116片(“VV116”)作為潛在呼吸道合胞病毒(“RSV”)抑制劑的臨牀前體內藥效研究成果於Nature旗下刊物《信號轉導和靶向治療》(Signal Transduction and Targeted Therapy,STTT,IF:18.187)在線發表。

研究發現,VV116在RSV多個敏感細胞繫上具有優異的抗病毒效果。在小鼠模型上,VV116具有較高的口服生物利用度、良好的組織分佈和顯著優利巴韋林的抗病毒效果,且能緩解肺部組織的病理損傷情況。該研究為治療RSV感染提供了有價值的臨牀候選藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account